Università LUM Giuseppe Degennaro - sito della Ricerca Institutional Research Information System

ROCCA, BIANCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.529
NA - Nord America 2.684
SA - Sud America 2.406
EU - Europa 684
AF - Africa 379
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 1
Totale 9.692
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.535
BR - Brasile 1.885
SG - Singapore 1.059
VN - Vietnam 1.037
CN - Cina 803
MA - Marocco 251
AR - Argentina 219
HK - Hong Kong 156
DE - Germania 139
ID - Indonesia 134
IT - Italia 116
EC - Ecuador 109
PK - Pakistan 89
GB - Regno Unito 69
RU - Federazione Russa 67
MX - Messico 66
FR - Francia 64
IN - India 62
BD - Bangladesh 58
CO - Colombia 56
ZA - Sudafrica 48
PY - Paraguay 43
AT - Austria 42
CA - Canada 40
CL - Cile 30
FI - Finlandia 27
NL - Olanda 25
VE - Venezuela 23
ES - Italia 22
UA - Ucraina 21
PE - Perù 20
EG - Egitto 19
IQ - Iraq 16
PL - Polonia 16
DZ - Algeria 15
KE - Kenya 15
BG - Bulgaria 13
TR - Turchia 13
TN - Tunisia 12
UY - Uruguay 12
DO - Repubblica Dominicana 11
JP - Giappone 11
UZ - Uzbekistan 11
KZ - Kazakistan 10
PH - Filippine 10
SA - Arabia Saudita 9
AL - Albania 8
AU - Australia 8
BO - Bolivia 8
SE - Svezia 7
EE - Estonia 6
HN - Honduras 6
AZ - Azerbaigian 5
KR - Corea 5
MD - Moldavia 5
PA - Panama 5
RO - Romania 5
SN - Senegal 5
AE - Emirati Arabi Uniti 4
CR - Costa Rica 4
CU - Cuba 4
IL - Israele 4
MY - Malesia 4
NP - Nepal 4
SK - Slovacchia (Repubblica Slovacca) 4
TT - Trinidad e Tobago 4
BE - Belgio 3
BH - Bahrain 3
CH - Svizzera 3
GT - Guatemala 3
JO - Giordania 3
KW - Kuwait 3
MK - Macedonia 3
PS - Palestinian Territory 3
RS - Serbia 3
SV - El Salvador 3
AO - Angola 2
BA - Bosnia-Erzegovina 2
CG - Congo 2
ET - Etiopia 2
IE - Irlanda 2
JM - Giamaica 2
KG - Kirghizistan 2
KH - Cambogia 2
LT - Lituania 2
OM - Oman 2
PT - Portogallo 2
BF - Burkina Faso 1
BS - Bahamas 1
BW - Botswana 1
BY - Bielorussia 1
CD - Congo 1
CI - Costa d'Avorio 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
GA - Gabon 1
GE - Georgia 1
GR - Grecia 1
GY - Guiana 1
HU - Ungheria 1
Totale 9.678
Salva come PNG Salva come JPEG
Città #
Dallas 1.232
Singapore 535
Ho Chi Minh City 399
Ashburn 277
The Dalles 261
San Jose 239
Hefei 228
Casablanca 225
Hanoi 196
São Paulo 158
Hong Kong 153
Beijing 90
Islamabad 71
Rio de Janeiro 55
New York 51
Haiphong 48
Columbus 38
Da Nang 38
Frankfurt am Main 38
Guayaquil 38
Curitiba 37
Los Angeles 37
Santa Clara 36
Munich 31
Belo Horizonte 30
Biên Hòa 29
Chicago 29
Quito 29
Brasília 27
Rome 26
Thái Bình 24
Helsinki 23
Hải Dương 22
Orem 22
Porto Alegre 22
Buenos Aires 20
Campinas 20
Milan 20
Ninh Bình 20
Jakarta 18
Piracicaba 18
Amsterdam 17
Asunción 17
Barnet 17
Ha Long 17
Johannesburg 17
Guarulhos 16
Nuremberg 16
Chennai 15
Fortaleza 15
Sorocaba 15
Can Tho 14
Salvador 14
Toronto 14
Vienna 14
Bắc Giang 13
São José do Rio Preto 13
Bắc Ninh 12
Cairo 12
Dhaka 12
Moscow 12
Nairobi 12
Thái Nguyên 12
Viamão 12
Council Bluffs 11
Hillsboro 11
Mexico City 11
Osasco 11
Phủ Lý 11
Recife 11
Ribeirão Preto 11
Bogotá 10
Goiânia 10
Hortolândia 10
London 10
Montevideo 10
Rabat 10
Surabaya 10
Tokyo 10
Warsaw 10
Duque de Caxias 9
Durban 9
Itapevi 9
Manaus 9
Montreal 9
Nova Friburgo 9
Rio Claro 9
Roubaix 9
Santos 9
Sumaré 9
Tashkent 9
Bauru 8
Blumenau 8
Boston 8
Brooklyn 8
Catanduva 8
Chapecó 8
Diadema 8
Düsseldorf 8
Feira de Santana 8
Totale 5.576
Salva come PNG Salva come JPEG
Nome #
Management of cancer-associated venous thromboembolism: Perspectives on optimizing current therapeutics with a focus on factor XI inhibition 263
Rethinking aspirin responsiveness in coronary surgery: True resistance or misinterpretation 195
2025 ESC/EACTS Guidelines for the management of valvular heart disease 181
2025 ESC/EACTS Guidelines for the management of valvular heart disease 171
2024 EACTS Guidelines on perioperative medication in adult cardiac surgery 85
Cardio-oncology: Emerging Concepts in Cardiovascular Sequelae of Cancer Therapies, Translational Research and Reverse Cardio-oncology 81
2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy 77
2024 ESC Guidelines for the management of peripheral arterial and aortic diseases 75
2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) 74
A randomized, double-blind trial of three aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia 68
2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 68
2024 EACTS guidelines on perioperative medication in adult cardiac surgery: embracing precision medicine driven by strong evidence-based methodology 67
2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes 62
2023 ESC Guidelines for the management of acute coronary syndromes 62
EHA Guidelines on Management of Antithrombotic Treatments in Thrombocytopenic Patients With Cancer 62
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD 61
A case of coloboma in a newborn to a woman taking mycophenolate mofetil in pregnancy after kidney transplantation 60
Aspirin, stroke and drug-drug interactions 59
Reversal of direct oral anticoagulants: guidance from the SSC of the ISTH 59
Acceptability of aspirin for cancer preventive therapy: a survey and qualitative study exploring the views of the UK general population 58
Stress-induced salivary cortisol secretion during hypobaric hypoxia challenge and in vivo urinary thromboxane production in healthy male subjects 58
A Genome-Wide Association Study of Diabetic Kidney Disease in Subjects With Type 2 Diabetes 58
Prostaglandins and other eicosanoids 57
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD 56
2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA) 55
Abnormal Megakaryopoiesis and Platelet Function in Cyclooxygenase-2-Deficient Mice 55
Reprogramming Epigenetic Changes Blunts p66Shc-induced Vascular Dysfunction In Experimental and Human Obesity: Insights for Mechanisms-Based Therapeutic Strategies 55
A randomized, double-blind trial of three aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia 55
Key priorities for the implementation of the 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes in low-resource settings 53
Acute, periprocedural and longterm antithrombotic therapy in older adults: 2022 Update by the ESC Working Group on Thrombosis 53
Prolonged fasting promotes systemic inflammation and platelet activation in humans: A medically supervised, water-only fasting and refeeding study 53
A case of coloboma in a newborn to a woman taking mycophenolate mofetil in pregnancy after kidney transplantation 53
2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: A joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA) 52
Effects of low-dose rivaroxaban combined with low-dose aspirin versus low-dose aspirin alone on in vivo platelet activation, endothelial function and inflammation in type 2 diabetes patients with stable atherosclerotic disease: the RivAsa randomized, crossover study 51
Characterization of aspirin esterase activity in health and disease: In vitro and ex vivo studies 51
The lifespan determinant p66shc drives obesity-induced oxidative stress, mitochondrial dysfunction and vascular inflammation 50
Aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: A new perspective 50
Safety of Antithrombotic Agents in Elderly Patients with Acute Coronary Syndromes 50
Platelet reactivity in patients with stable cardiovascular disease using aspirin: correlation between different tests and association with subject characteristics 50
In Vivo Platelet Activation in Impaired Glucose Tolerance and During Progression of Type 2 Diabetes: a Cross-sectional and Longitudinal Study 50
Characterization of aspirin esterase activity in health and disease: In vitro and ex vivo studies 50
Platelet and megakaryocyte phenotypes of COX-2 deletion 50
EHA Guidelines on Management of Antithrombotic Treatments in Thrombocytopenic Patients With Cancer 49
Effect of very long-term storage and multiple freeze and thaw cycles on 11-dehydro-thromboxane-B2 and 8-iso-prostaglandin F2α, levels in human urine samples by validated enzyme immunoassays 49
Ticagrelor and Statins: Dangerous Liaisons? 49
Kinetics of free platelet decrease after ADP: effect of fibrinogen binding inhibitors 49
Infective Endocarditis and Antithrombotic Therapy 49
EQUIVALENZE DI CLASSE TE RAPEUTICA NELL'AREA DEGLI ANTICOAGULANTI ORALI 49
Platelet progenitors: the hidden drug target 48
Update on antithrombotic therapy and body mass. A Clinical consensus Statement of the ESC Working Group on Cardiovascular Pharmacotherapy and the ESC Working Group on Thrombosis 48
Polycythemia Vera: the natural history of 1213 patients followed for 20 years 48
Twice Daily Dosing Normalyzes the Impaired Antiplatelet Effect of Low-Dose Aspirin Due to Enhanced Platelet Turnover in Patients Undergoing On-Pump Cardiac Surgery 48
Role of Oxidative Stress in the Pathogenesis of Atherothrombotic Diseases 47
Clinical guidelines for a dry land: challenges in developing recommendations for DOAC management in emergent cardiac surgery 47
Antithrombotic therapy and revascularisation strategies in people with diabetes and coronary artery disease 47
Qualitative and quantitative modifications of von willebrand factor in patients with essential thrombocythemia and controlled platelet count 47
Management of dyslipidaemia in patients with comorbidities—facing the challenge: type 1 diabetes mellitus 46
Factor XI and Atrial Fibrillation: A Mismatched Pairing? 46
Pseudo-acquired vWD in essential thrombocythemia: the role of platelets 46
Physiologically based modelling of the antiplatelet effect of aspirin: A tool to characterize drug responsiveness and inform precision dosing 46
Obesity is associated with in vivo platelet activation and impaired responsiveness to once-daily, low-dose aspirin 46
Evidence for a founder effect of the MPL-S505N mutation in eight Italian pedigrees with hereditary thrombocythemia 46
Heat extremes and cardiovascular diseases: a scientific statement of the Association of Cardiovascular Nursing & Allied Professions, Association for Acute Cardiovascular Care, European Association of Preventive Cardiology, Heart Failure Association, European Heart Rhythm Association of the ESC, the ESC Council on Hypertension, the ESC Council on Stroke, and the ESC Working Group on Cardiovascular Pharmacotherapy 45
Obesity is associated with impaired responsiveness to once-daily low-dose aspirin and in vivo platelet activation 45
Obesity is associated with impaired responsiveness to once-daily low-dose aspirin and in vivo platelet activation 45
Thrombin-thrombomodulin interaction: energetics and potential role of water as an allosteric effector 44
Aspirin for primary prevention: new scores for old questions? 44
The ESC Working Group on Cardiovascular Pharmacotherapy: continuity through transformation 44
Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis 44
Low-dose aspirin in polycythaemia vera: A pilot study 44
The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design - implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting. (Rocca B and De Stefano V co-first Authors) 43
Effect of low-dose and standard-dose aspirin on PGE2 biosynthesis among individuals with colorectal adenomas: A randomized clinical trial 43
Frailty in cardiology: definition, assessment and clinical implications for general cardiology. A consensus document of the Council for Cardiology Practice (CCP), Acute Cardiovascular Care Association (ACCA), Association of Cardiovascular Nursing and Allied Professions (ACNAP), European Association of Preventive Cardiology (EAPC), European Heart Rhythm Association (EHRA), Council on Valvular Heart Diseases (VHD), Council on Hypertension (CHT), Council of Cardio-Oncology (CCO), Working Group (WG) Aorta and Peripheral Vascular Diseases, WG e-Cardiology, WG Thrombosis, of the European Society of Cardiology, European Primary Care Cardiology Society (EPCCS) 43
Very-low-dose twice-daily aspirin maintains platelet inhibition and improves haemostasis during dual-antiplatelet therapy for acute coronary syndrome 43
Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE) 43
2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC 43
Thromboxane biosynthesis and future events in diabetes: the ASCEND trial 43
In Silico Modeling of the Antiplatelet Pharmacodynamics of Low-dose Aspirin in Health and Disease 43
Farmaci antipiastrinici 43
Genetic Deletion of P66 (Shc) Protects Against Obesity-Induced Mitochondrial Dysfunction, Oxidative Stress and Vascular Inflammation 43
Oral anticoagulation in patients with left ventricular thrombus: a systematic review and meta-analysis 43
Aspirin inhibits cancer stem cells properties and growth of glioblastoma multiforme through Rb1 pathway modulation 43
Antithrombotic therapy in patients with acute coronary syndrome complicated by cardiogenic shock or out-of-hospital cardiac arrest: a Joint Position Paper from the European Society of Cardiology (ESC) Working Group on Thrombosis, in association with the Acute Cardiovascular Care Association (ACCA) and European Association of Percutaneous Cardiovascular Interventions (EAPCI) 42
Expression and activity of cyclooxygenase isoforms in skeletal muscles and myocardium of humans and rodents 42
Pathophysiology of Thrombosis in Peripheral Artery Disease 42
Position of nonmuscle myosin heavy chain IIA (NMMHC-IIA) mutations predicts the natural history of MYH9-related disease 42
Directed vascular expression of the thromboxane A2 receptor results in intrauterine growth retardation 41
Lipid and protein oxidation contribute to a prothrombotic state in patients with type 2 diabetes mellitus 41
Circulating endothelial progenitor cells and residual in vivo thromboxane biosynthesis in low-dose aspirin-treated polycythemia vera patients 41
Cystic fibrosis transmembrane conductance regulator (CFTR) expression in human platelets: Impact on mediators and mechanisms of the inflammatory response 41
Long-term pharmacodynamic and clinical effects of twice- versus once-daily low-dose aspirin in essential thrombocythemia: The ARES trial 41
The Key Contribution Of Platelet And Vascular Arachidonic Acid Metabolism To The Pathophysiology Of Atherothrombosis 40
Nonsteroidal Antiinflammatory Drugs: Past, Present and Future 40
The linkage between binding of C-terminal domain of hirudin and amidase activity in human alpha-thrombin 40
In Vivo and In Vitro Effects of Different Anaesthetics on Platelet Function 39
Highlights from the 2019 International Aspirin Foundation Scientific Conference, Rome, 28 June 2019: benefits and risks of antithrombotic therapy for cardiovascular disease prevention 39
Drug Insight: Aspirin Resistance - fact or fashion? 39
In Vivo Platelet Activation and Aspirin Responsiveness in Type 1 Diabetes Mellitus 39
Thromboxane biosynthesis and future events in diabetes: the ASCEND trial 39
Cyclooxygenase and prostaglandin: shaping up the immune response 39
Totale 5.601
Salva come PNG Salva come JPEG
Categoria #
all - tutte 63.132
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 63.132
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2024/20251.362 0 0 0 343 104 91 22 52 199 166 236 149
2025/20268.576 242 1.074 1.894 2.978 171 120 641 519 396 541 0 0
Totale 9.938